Transforming from Regional Leader to Global Premier:

A Clear Strategic Path for Growth and Globalization

SAN FRANCISCO and SUZHOU, China, Aug. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2026 interim results and 2030 strategic vision.

Dr. Michael Yu, Founder, Chairman of the Board and CEO of Innovent, stated: "Looking back over the past fifteen years, Innovent has completed two key transformations: from 2016 to 2020, we transformed from an R&D-driven biotech company into a biopharmaceutical company with full-value-chain capabilities spanning R&D, manufacturing, and commercialization; from 2021 to 2025, we progressed from a long-term investment phase into a biopharmaceutical company that achieved revenue over RMB 10 billion and full-scale profitability. 2026 marks Innovent's best strategic window to date, and it is against this backdrop that we have set forth our new strategic goals for 2030. We have both the resolve and the confidence to drive our third critical transformation: evolving from a regional leading biopharmaceutical company into a global premier biopharma with global business operational capabilities.

In the first half of 2026, Innovent delivered strong growth in both revenue and profit, further reinforcing our leading position in China's biopharmaceutical industry and highlighting our scarce value in both certainty and growth potential. At the same time, over the past ten months, we have reached multiple strategic collaborations with global multinational pharmaceutical leaders including Takeda, Eli Lilly, and Pfizer, while also partnering with biotechs such as Ollin and Spero to advance the global development of our differentiated pipeline. Our partnered pipeline now spans more than 20 assets, including 5 co-development and co-commercialization ("Co-Co") programs, with an aggregate deal value reaching USD 34 billion, representing more than 30% of the total out-licensing value among Chinese pharmaceutical companies over the same period¹. Innovent stands at the most favorable strategic window in its development. We will continue to pursue high-quality growth in revenue and profit, guided by clear strategy and disciplined execution — strengthening and amplifying our 'dual-engine' advantage across oncology and general biomedicine, accelerating our global expansion, and advancing toward our 2030 strategic goals, so as to continue creating long-term value for our shareholders and society."

 A Visible Growth Path: Scale and Profitability Advancing in Parallel

In the first half of 2026, Innovent reached RMB 8.6 billion in total revenue, representing 45% year-over-year growth, while product revenue reached RMB 8.2 billion, up 57% year over year. Building on the RMB 10 billion-plus revenue scale, Innovent maintained strong growth momentum, with its dual-engine strategy of oncology and general biomedicine continuing to deliver.

Rapid revenue growth, coupled with continued improvements in operational efficiency, further drove improvements in profitability. IFRS net profit for the first half of the year was approximately RMB 1.3 billion, representing approximately 50% year-over-year growth, while Non-IFRS net profit reached RMB 1.7 billion, up 41% year over year. Innovent has entered a new stage characterized by simultaneous expansion in scale and improvement in earnings quality, setting a new paradigm for high-quality growth among biopharmaceutical companies.

As of July 31, 2026, Innovent held RMB 30.2 billion in cash reserves, equivalent to approximately US$4.5 billion. In addition, we continued to generate positive cash flow, providing a strong financial foundation for long-term growth.

Vision 2030: From China Leader to Global Premier Biopharma

Building on high-quality growth and systematic portfolio development, the Company has underpinned its 2030 development goals.

• Revenue Scale: By 2030, we target to achieve total revenue of RMB 35–40 billion, largely driven by organic expansion from the existing business and pipeline.
• Sustainable Profitability: By 2030, we aim to benchmark our profit margin to top-tier pharmaceutical companies, through continued revenue expansion and efficiency improvements.
• Global Innovation: By 2030, we aim to advance at least five molecules into global MRCT Phase 3 development, achieve product launches in key markets, i.e. U.S. and Europe with international revenue emerging.
• Globalization: building global infrastructure and business operating capabilities, truly transforming into a global premier biopharmaceutical company.

From "Product-led Growth" to "Portfolio-Driven Growth," with Dual Growth Engines Unleashing New Momentum

China's Leading Oncology Franchise: Strengthening Core Oncology Leadership While Expanding Strategically into Key Growth Areas

In oncology, Innovent has established a strong product portfolio and brand presence across core indications including lung cancer, gastrointestinal cancers and hematological malignancies. Focusing on the next-generation "IO + ADC" innovation strategy, the Company is advancing next-generation assets including IBI363 (PD-1/IL-2^α-biased), IBI343 (CLDN18.2 ADC), and IBI3003 (GPRC5D/BCMA/CD3) into late-stage clinical development, establishing long-term growth drivers and competitive advantages across multiple strategic areas.

Meanwhile, through its collaboration with Lilly on Verzenio® (abemaciclib) in breast cancer, we have strategically gained an important entry point into this major high-incidence tumor type. This asset lays the foundation for upcoming in-house pipeline programs such as IBI354(HER2 ADC) and IBI3014(PD-L1/TROP2 ADC), and paves the way for a more systematic presence in breast cancer.

General Biomedicine Franchise Emerged as a New Growth Engine

In general biomedicine, Innovent has established a clear framework across four major chronic disease areas—metabolic, cardiovascular, ophthalmology and autoimmune—and this franchise has become another core pillar of Innovent.

SYCUME® (Teprotumumab, IGF-1R antibody), China's first innovative therapy for thyroid eye disease in 70 years; Mazdutide, the world's first and only approved GCG/GLP-1 dual-receptor agonist for obesity and type 2 diabetes; and SINTBILO® (tafolecimab injection), the first China-domestic PCSK9 inhibitor included in the NRDL—all exhibited robust performance. PECONDLE® (picankibart injection, IL-23p19 antibody), the anchor asset in autoimmune diseases, was also approved at the end of 2025.

At the same time, our next‑generation metabolic and obesity pipeline – including IBI3032 (once‑daily oral GLP‑1), IBI3042 (once‑weekly oral GLP‑1), IBI3040 (Amylin), IBI3046 (INHBE siRNA) and IBI3030 (monthly PCSK9‑GGG) – provides deep, long‑term growth reserves in global obesity and metabolic disease. In cardiovascular & metabolism, autoimmune and ophthalmology, we are following a "flagship products life cycle management + next‑generation innovation" strategy to build focused product clusters and durable competitive positions in each area.

Three Late-Stage Global Assets Unlocking More Than US$60 Billion Total Addressable Market (TAM), and 20+ Partnered Programs Accelerating Global Innovation

Innovent is advancing global development of its core assets through multiple collaboration models. Three key assets have entered, or are about to enter, global multi-regional Phase 3 trials, with a combined addressable market estimated at over US$60 billion, and are expected to be major value drivers in the coming years:

IBI363 (PD-1/IL-2^α-biased, Takeda R&D Code: TAK-928): Next-gen IO cornerstone, potential TAM over US$40 billion for first wave of indications, global co-development with Takeda

• A global multi-regional Phase 3 study (MarsLight-11) in IO-resistant squamous non-small cell lung cancer (NSCLC) is ongoing, and with expansion into IO-resistant non-squamous NSCLC in preparation.
• A pivotal Phase 2 study of IBI363 in melanoma in China is expected to read out in the second half of 2026, potentially supporting the first NDA submission for IBI363.
• IBI363 has demonstrated preliminary positive PoC results in first-line NSCLC. PoC studies in first-line NSCLC and first-line colorectal cancer are ongoing, with additional PoC studies being advanced across other tumor types, further supporting its potential as a next-generation IO backbone therapy.

Arcotatug Tavetecan (CLDN18.2 ADC, Innovent/Takeda R&D Code: IBI343/TAK-921): Globally First NDA stage Next-Generation Fc-Silenced CLDN18.2 ADC, potential TAM over US$8 billion

• The China-Japan multicenter Phase 3 study completed its first interim analysis and achieved primary endpoint. The NDA submission has been accepted by NMPA for the treatment of CLDN18.2-positive advanced gastric cancer in later-line settings.
• A Phase 3 study in first-line pancreatic cancer is planned to initiate in China.
• International multicenter Phase 1 and PoC studies in first-line pancreatic cancer and first-line gastric cancer are ongoing.

IBI324 (VEGF/ANG2, Ollin R&D Code: OLN324): Potential best-in-disease retinal therapy, potential TAM US$15 billion

• Our partner Ollin Biosciences reported positive results from the Phase 1b JADE head-to-head study against faricimab in nAMD and DME patients in the U.S.
• Ollin plans to initiate global multi-regional Phase 3 studies in DME and nAMD in the second half of 2026, and through collaboration with Innovent, to conduct patient enrollment in China and South Korea.

Diversified Partnerships to Accelerate Global Innovation

• Over the past 10 months, Innovent has entered into strategic multi-product collaborations with global multi-national pharmaceutical companies including Takeda, Lilly and Pfizer, while partnering with biotech companies such as Ollin and Spero to rapidly validate differentiated pipeline programs in selected disease areas. The aggregate deal value reaching US$34 billion, covering more than 20 pipeline programs, among which five are "Co-Co" assets.
• Leveraging diversified partnership models, the Company will progressively build overseas R&D and commercialization capabilities and evolve into a truly world-class biopharmaceutical company with global business operating capabilities.

High-Quality Manufacturing Standards

• Innovent operates advanced manufacturing facilities built to international standards and our Suzhou manufacturing site has recently undergone and successfully passed a Good Manufacturing Practice (GMP) inspection conducted by the European Medicines Agency (EMA), and has obtained the corresponding GMP certificate.
• Total operational capacity of 140,000 liters, accounting for 20% of China's total biologic manufacturing capacity. Suzhou site houses 60,000 liters of antibody capacity and ADC commercial lines; Hangzhou site has 80,000 liters of antibody capacity, supporting global supply and CDMO services.

Sustainable Development and ESG Commitment

• 9,000 employees worldwide, with global R&D centers in San Francisco Bay Area, Shanghai and Suzhou.
• Over 3,000 new cancer patients initiate Innovent therapies daily; more than 10 million patients have benefited to date.
• Maintained MSCI ESG AAA rating, leading China's biopharmaceutical industry.
• First innovative biopharma constituent of the Hang Seng Index ("blue-chip" status).
• Launched community health initiatives including the MV 'Weight Management Made Easy' and documentary 'Down in Weight, Up in Life' to promote science-based healthy weight management.
• Published patient education materials on thyroid eye disease and weight management to enhance public health awareness.
• Implemented multiple patient assistance programs, benefiting over 200,000 patients with drug donations valued at over RMB 4 billion.
• Received honors including "Healthcare Public Welfare Pioneer" and "China Public Welfare Enterprise".
• Created over 2,700 jobs for new graduates.
• Cumulative taxes and contributions exceeding RMB 9 billion.

Note:

1. Data source: Next Pharma database.

About Innovent Biologics

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 20 products in the market. It has 1 asset in NMPA NDA review, 5 assets in Phase 3 or pivotal clinical trials and 14 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Lilly, Takeda, Pfizer, Roche, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

Guided by the motto, "Start with Integrity, Succeed through Action" Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement:

1) Innovent does not recommend the use of any unapproved drug (s)/indication (s).
2) Ramucirumab (Cyramza) and Selpercatinib (Retsevmo), Pirtobrutinib (Jaypirca) and abemaciclib (Verzenios) were developed by Eli Lilly and Company.
Disclaimer: Innovent does not recommend any off-label usage.

Forward-Looking Statements of Innovent Biologics

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions.

TAGUIG CITY, Philippines, Aug. 25, 2026 /PRNewswire/ -- Yadea Philippines and J&T Express have announced a strategic partnership to accelerate the adoption of electric vehicles in the local logistics sector. Manila will serve as the pilot with 1,000 units rolling out initially, followed by nationwide expansion.

As the global No.1 electric two-wheeler brand for nine consecutive years, Yadea operates over 70 branded sales and service centers, with flagship models like EPOC and CL8. Partnering with J&T Express, a leading Philippine courier, will accelerate Yadea's entry into the local logistics market. Together, they aim to optimize logistics and drive a greener, low-carbon future for express delivery, reflecting the companies' shared commitment to sustainable urban mobility and environmental stewardship.

YADEA ST13 is an electric delivery tricycle designed for high-frequency, short-distance commercial delivery scenarios. It integrates energy-efficient transport systems purpose-built for high-frequency urban dispatch. The unit features a weight-reducing mesh cargo box that directly optimizes battery range, paired with premium A+ grade puncture-resistant steel-wire tires designed for continuous delivery operational capability.

Yadea General Manager of the Philippines Wang Chun stated, "This cooperation reflects a deep synergy between product capability and logistics networks, representing a practical response to the country's demand for green transportation. We hope our locally tailored electric vehicles allow delivery personnel to ride with greater peace of mind and operate more efficiently, injecting tangible momentum into low-carbon urban logistics."

J&T Express Philippines National Capital Region Key Account Manager Mary Andaya stated, "Through this collaboration, we are actively integrating electric vehicle solutions into our last-mile operations. This initiative optimizes our daily workflow while aligning with our shared direction of collaborating on the large-scale adoption of electric tricycles for deliveries to enhance delivery efficiency within the local logistics sector."

About YADEA

YADEA is a leading electric mobility brand and has ranked No.1 globally in electric two-wheeler sales for nine consecutive years. Driven by innovation, YADEA provides electric two-wheelers, electric tricycles and other mobility solutions to users around the world through its integrated capabilities in R&D, manufacturing, products channels and services.

About J&T Express Philippines

J&T Express Philippines, a nationwide logistics provider established in 2019, offers express delivery services via land, air, and sea. The company operates automated distribution centers and maintains extensive trucks and delivery services that run 24/7, ensuring that packages are safely delivered across the Philippines.

Contact:
[email protected]

NVIDIA Corporation (NVDA.US) announced that its Groq 3 LPX chips have entered full-scale production.

Senior Director Dion Harris said the Groq chips will be deployed alongside the Vera CPU and Rubin GPU at cloud service provider Nebius, with launch scheduled for later this year.

NVIDIA is accelerating production and customer supply of Groq chips, reflecting the growing importance of low-latency inference technology.

The technology helps AI agents improve response speed in applications such as coding and reduces user waiting time. NVIDIA noted that cloud companies can charge higher fees for related token services.

NVIDIA acquired Groq assets for USD20 billion in December 2025, marking the company's largest-ever acquisition. Groq chips are manufactured by Samsung, while TSMC (TSM.US) produces NVIDIA's GPUs.
~

AASTOCKS Financial News
Website: www.aastocks.com

• Group total revenue increased to RMB 3,701.4 million, representing 37.0% period-over-period growth on an AER^[1] basis (41.5% growth on a CER^[2] basis)
• Gross profit grew by 40.6% period-over-period, reaching RMB 1,371.3 million. Gross profit margin was 37.0%, a 0.9 percentage points increase compared to 2025 1H
• Adjusted net profit attributable to owners of the Company increased by 37.4% period-over-period, reaching RMB 1,027.3 million. The margin of adjusted net profit attributable to owners of the Company remained stable at 27.8%, a 0.1 percentage increase compared to 2025 1H
• The total global customer base expanded to over 810 companies, and 15 out of the TOP 20 global pharmaceutical companies have partnered with us
• The total number of iCMC projects reached 328, with 51 newly signed iCMC projects
• The commercial and PPQ pipeline: 2 commercial projects; 21 PPQ projects in total, with 2 PPQ projects newly signed in 2026 1H
• The service backlog grew to approximately US$2.0 billion, a solid 50.4% increase period-over-period. Including the upcoming milestone fee, total backlog reached approximately US$2.2 billion, up 62.2% period-over-period

SHANGHAI, Aug. 24, 2026 /PRNewswire/ -- WuXi XDC Cayman Inc. (the "WuXi XDC" or the "Group", stock code: 2268.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) focused on the bioconjugate market, is pleased to announce its interim results for the six months ended June 30, 2026 (the "Reporting Period").

CEO Comment

Dr. Jimmy Li, CEO of WuXi XDC, stated, "Our strong first-half 2026 performance reflects the continued execution of our long-term strategy and increasing global demand for integrated bioconjugate CRDMO services. During the period, we further strengthened our capabilities through the successful integration of BioDlink, continued expansion of our global manufacturing network, and advancement of our proprietary technology platforms. Looking ahead, we remain committed to empowering customers through our 'Enable, Follow and Win the Molecule' strategy and are well positioned to capture the significant opportunities emerging across the broader XDC market."

Financial Highlights for Interim Results of 2026

Revenue

• The Group's revenue increased to RMB 3,701.4 million for the six months ended June 30, 2026, representing 37.0% period-over-period growth on an AER basis (41.5% on a CER basis).  
• This increase was primarily attributable to (i) the growth in the number of customers and projects, driven by continued active development of the global ADC and broader bioconjugates market, (ii) the increasing market share through the Group's established position as a leading ADC CRDMO service provider in that market, and (iii) the steady advancement of the Group's projects into later stages.

Gross Profit and Its Margin

• The Group's gross profit increased by 40.6 % period-over-period to RMB 1,371.3 million, with a gross profit margin of 37.0 % for the six months ended June 30, 2026, a 0.9 percentage points increase compared to that of 2025 1H.
• This improvement is driven by (i) the continuous enhancement of our overall operation and manufacturing efficiency, (ii) the utilization ratio of production facilities continued to maintain at a high level, mainly due to strong customer demand, (iii) the successful ramp-up of operating production lines, and(iv) increased contribution from higher value-added services.

Adjusted Net profit attributable to owners of the Company and Its Margin

• The Group's adjusted net profit attributable to owners of the Company increased by 37.4% period-over-period to RMB 1,027.3 million, demonstrating the strong profit growth momentum of the Group's core operating business. The margin of adjusted net profit attributable to owners of the Company remained stable at 27.8 % for the six months ended June 30, 2026, a 0.1 percentage points increase compared to that of 2025 1H.
• This growth and improvement were primarily driven by the factors above and continuous disciplined control of SG&A expenses.

Customers and Projects Highlights for Interim Results of 2026

• We have continuously expanded our customer base, reaching a cumulative total of 814.
• The "Enable, Follow, and Win the Molecule" strategy continued to drive sustained and rapid project growth. The total number of integrated projects ("iCMC projects") is 328, with 51 newly signed integrated projects.
• The Group has successfully secured 21 PPQ projects, with 2 new PPQ projects signed in 2026 1H.
• The Group currently holds 2 commercial-stage projects, demonstrating its emerging track record and proven capabilities in commercial manufacturing.
• The Group has a diversified project base covering both innovative ADC and broader bioconjugate ("XDC") projects. The total number of integrated ADC projects reached 286, and the number of integrated XDC projects increased to 42.
• In 2026 1H, the Group explored over 3,100 molecules of multiple modalities, including bispecific ADCs, dual-payload ADCs, degrader-antibody conjugates (DAC), antibody-oligonucleotide conjugates (AOC), antibody-peptide conjugates (APC), etc. Notably, the Group explored over 22,000 ADC/XDC molecules cumulatively as at the end of the Reporting Period.

Development of Fully Integrated R&D Technology Platform During 2026 1H

The Group provides customers with innovative conjugation and payload-linker technologies to accelerate the development of next-generation bioconjugates. Multiple customer programs enabled by the WuXiDARx™, X-LinC™, and WuXi Payload-Linker™ platforms have advanced from PCC to iCMC and clinical development, demonstrating the robustness, scalability, and broad applicability of the Group's integrated technology platform.

WuXiDARx™ - Conjugation platform

WuXiDARx™ is a clinically validated conjugation platform that enables highly homogeneous ADCs, APCs, AOCs, and dual-payload ADCs, supporting diverse bioconjugate modalities from discovery through clinical development. The platform has successfully facilitated customers bringing 8 ADC pipelines from preclinical stage to clinical stage.

• WuXiDAR4™ enhances ADC homogeneity and therapeutic index (TI), enabling over 10 iCMC programs, including 8 in clinical development.
• WuXiDAR2™ delivers highly homogeneous ADCs and APCs, enabling the first DAR2 ADC program advance to iCMC-ready stage.
• WuXiDAR1™ delivers highly homogeneous DAR1 AOCs, validating the platform for AOC development.
• WuXiDARx™ technology also enables sequential, precise dual-payload conjugation via native interchain cysteine sites without antibody engineering or enzymatic conjugation, offering a streamlined, cost-effective single-platform solution. The technology has successfully enabled first dual-payload ADC program to iCMC-ready stage.

WuXi Payload-Linker™ - Payload-linker platform

WuXi Payload-Linker™ technologies enable next-generation ADCs with differentiated mechanisms of action, improved therapeutic index, and enhanced developability through proprietary payload and hydrophilic linker technologies.

• WuXiTecan-2™ is a proprietary exatecan-based payload-linker platform featuring improved hydrophilicity, plasma stability, and robust in vivo efficacy. The technology has been successfully applied to 3 iCMC-stage customer programs through technology licensing agreements with Earendil Labs and a European biotech company in 2026, demonstrating its strong developability and translational potential.  Notably, a WuXiTecan-2™- based dual-payload ADC (MMAE + WuXiTecan-2™) successfully achieved PCC and advanced into iCMC development, highlighting the platform's ability to enable next-generation ADC development.
• WuXiLinker™ is a proprietary hydrophilic linker technology that enables hydrophobic payloads with improved developability, stability, and conjugation performance. The technology has been successfully extended to multiple payloads, including WuXiMMAE™, WuXiATRi™, and WuXiEribulin™, and extended beyond established payloads to support the development of next-generation payload-linker technologies, including DDR inhibitors and other differentiated hydrophobic payloads.
• X-LinC™ is a proprietary stable conjugation connector that replaces conventional maleimide chemistry, enhancing ADC stability through reduced payload-linker deconjugation and improved in vivo stability.

Capacity Expansion & Business Operation Updates During 2026 1H

• The total number of full-time employees increased to 3,628 in the Group, driven by rapid business growth and the Group's capacity expansion. WuXi XDC's standalone headcount grew to over 3,100 employees. The Group continued to invest in talent development, sustaining a high-caliber standalone and domestic workforce, with more than 50% of employees holding master's degrees or above.
• All of the Group's manufacturing operations are conducted in accordance with the GMP regulations set by the FDA, EMA, and NMPA. The Group has completed 200+ GMP audits from global customers, including 27 audits by EU Qualified Persons.
• The acquisition of BioDlink in March 2026 increased the Group's manufacturing capacity, broadened its project portfolio, and expanded its client network.
• In August 2026, the Singapore facility's XmAb/XBCM3 achieved GMP release, marking the Group's first mAb and bioconjugates manufacturing site overseas. XDP4 is scheduled for GMP release by the end of August 2026.
• Future capacities build-out: The XDP5 and XDP6 expansions in Wuxi are designed to augment the Group's drug product manufacturing capacity, reinforcing our ability to support late-stage clinical and commercial-scale programs across diverse modalities, including ADCs, AOCs, and other novel bioconjugates. Meanwhile, XPLM2 in Jiangyin site secures vertical integration into the critical payload and linker supply chain.
• The Group was named the winner of "Best CDMO" for 3 consecutive year from 2023 to 2025, as well as "Best CRO" at the 2025 World ADC Awards.
• The Group is committed to ESG excellence, reflected in its "A" ratings from MSCI ESG (2026) and Wind ESG (2025), and its designation as an Industry ESG Leader by Morningstar Sustainalytics.

***

Key Financial Performance (For the Six Months Ended June 30)

About WuXi XDC

WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK) is a leading global CRDMO focused on bioconjugate market. It provides end-to-end contract research, development and manufacturing services for ADC and broader bioconjugates. For more information about WuXi XDC, please visit: www.wuxixdc.com

Contacts

Investor: [email protected]
Media: [email protected]
BD: [email protected]

Forward-Looking Statements

This presentation may contain certain "forward-looking statements" which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain, and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, and our ability to protect our customers' intellectual property. Our forward-looking statements in this presentation speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section.

Use of Adjusted Financial Measures and CER (Non-IFRS Measures)

The Group defines "adjusted net profit attributable to owners of the Company" as net profit attributable to owners of the Company after elimination of share-based compensation expense as non-cash expenditure, net foreign exchange loss or gain as non-operating item, non-recurring/one-off transaction costs as non-operating item, and net of interest income and finance costs as non-operating item. We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing underlying business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual and non-recurring items that we do not consider indicative of the performance of our business. However, the presentation of these non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies. The Company's functional currency is Renminbi ("RMB"). Given that a majority of the Group's service contracts are denominated in U.S. dollars ("USD"), the Group presents certain operating results on both an actual exchange rate ("AER") basis and a constant exchange rate ("CER") basis.

• Cash position^[i] was RMB40.48 billion (US$5.97 billion) as of June 30, 2026
• Quarterly total revenues were RMB19.74 billion, a 51.5% increase quarter-over-quarter
• Quarterly gross margin was 20.7%, an increase of 3.4 percentage points over the same period of 2025
• Quarterly vehicle margin was 12.1%, remained relatively stable quarter-over-quarter

GUANGZHOU, China, Aug. 24, 2026 /PRNewswire/ -- XPeng Inc. ("XPENG" or the "Company," NYSE: XPEV and HKEX: 9868), a leading global Physical AI company, today announced its unaudited financial results for the three months ended June 30, 2026.

Operational and Financial Highlights for the Three Months Ended June 30, 2026

• Total deliveries of vehicles were 103,295 for the second quarter of 2026, representing an increase of 0.1% from 103,181 in the corresponding period of 2025.
  
  
• XPENG's physical sales network had a total of 740 stores, covering 257 cities as of June 30, 2026.
  
  
• XPENG self-operated charging station network reached 3,780 stations, including 2,720 XPENG ultra-fast charging stations as of June 30, 2026.
  
  
• Total revenues were RMB19.74 billion (US$2.91 billion) for the second quarter of 2026, representing an increase of 8.0% from the same period of 2025, and an increase of 51.5% from the first quarter of 2026.
  
  
• Revenues from vehicle sales were RMB17.05 billion (US$2.51 billion) for the second quarter of 2026, representing an increase of 1.0% from the same period of 2025, and an increase of 55.0% from the first quarter of 2026.
  
  
• Gross margin was 20.7% for the second quarter of 2026, compared with 17.3% for the same period of 2025 and 20.6% for the first quarter of 2026.
  
  
• Vehicle margin, which is gross profit of vehicle sales as a percentage of vehicle sales revenue, was 12.1% for the second quarter of 2026, compared with 14.3% for the same period of 2025 and 12.1% for the first quarter of 2026.
  
  
• Net loss was RMB1.34 billion (US$0.20 billion) for the second quarter of 2026, compared with a loss of RMB0.48 billion for the same period of 2025 and a loss of RMB1.78 billion for the first quarter of 2026. Excluding share-based compensation expenses and fair value gain on derivative liability relating to the contingent consideration, non-GAAP net loss was RMB1.24 billion (US$0.18 billion) for the second quarter of 2026, compared with a loss of RMB0.39 billion for the same period of 2025 and a loss of RMB1.69 billion for the first quarter of 2026.
  
  
• Net loss attributable to ordinary shareholders of XPENG was RMB1.34 billion (US$0.20 billion) for the second quarter of 2026, compared with a loss of RMB0.48 billion for the same period of 2025 and a loss of RMB1.78 billion for the first quarter of 2026. Excluding share-based compensation expenses and fair value gain on derivative liability relating to the contingent consideration, non-GAAP net loss attributable to ordinary shareholders of XPENG was RMB1.24 billion (US$0.18 billion) for the second quarter of 2026, compared with a loss of RMB0.39 billion for the same period of 2025 and a loss of RMB1.69 billion for the first quarter of 2026.
  
  
• Basic and diluted net loss per American depositary share (ADS) were both RMB1.40 (US$0.21) and basic and diluted net loss per ordinary share were both RMB0.70 (US$0.10) for the second quarter of 2026. Each ADS represents two Class A ordinary shares.
  
  
• Non-GAAP basic and diluted net loss per ADS were both RMB1.29 (US$0.19), and non-GAAP basic and diluted net loss per ordinary share were both RMB0.65 (US$0.10) for the second quarter of 2026.
  
  
• Cash position was RMB40.48 billion (US$5.97 billion) as of June 30, 2026, compared with RMB42.09 billion as of March 31, 2026.

Management Commentary

"The back-to-back success of the GX and MONA L03 gives us greater confidence in our upcoming new models, as we translate our leading edge in smart technologies and design into more blockbuster products and stronger brand momentum," said Mr. Xiaopeng He, Chairman and CEO of XPENG. "The development of the mass-production version of XPENG's humanoid robot has recently reached several significant milestones. I believe XPENG will not only build one of China's most valuable humanoid robotics companies, but also become a global leader in physical AI, spearheading the large-scale adoption and commercialization of advanced general-purpose humanoid robots and autonomous driving technologies in China and overseas."

"During the second quarter of 2026, our operations remained resilient despite industry-wide cost pressures. Driven by breakthroughs in our premiumization and globalization efforts, our gross margin continued to exceed 20%," added Dr. Hongdi Brian Gu, Vice Chairman and Co-President of XPENG. "I expect the mass production and commercialization of physical AI technologies to accelerate over the coming year, generating meaningful gross profit growth to support our continued R&D investment in physical AI."

Recent Developments

Deliveries in July 2026

• Total deliveries were 38,027 vehicles in July 2026.
  
  
• As of July 31, 2026, year-to-date total deliveries were 204,004 vehicles.

Launch of MONA L03

On July 16, 2026, XPENG held the global launch event of MONA L03, the Next-Gen AI SUV Coupe, in Munich, Germany.

Entering into the Dogotix Share Purchase Agreement

On August 24, 2026, Dogotix Inc. (a subsidiary of the Company) entered into a share purchase agreement (the "Dogotix Share Purchase Agreement") with, among others, certain subscribers, pursuant to which such subscribers conditionally agreed to subscribe for certain shares to be newly issued by Dogotix Inc. at an aggregate purchase price of US$900 million. For details, please refer to the announcement of the Company dated August 24, 2026, in relation to, among others, the Dogotix Share Purchase Agreement.

Unaudited Financial Results for the Three Months Ended June 30, 2026

Total revenues were RMB19.74 billion (US$2.91 billion) for the second quarter of 2026, representing an increase of 8.0% from RMB18.27 billion for the same period of 2025 and an increase of 51.5% from RMB13.03 billion for the first quarter of 2026.

Revenues from vehicle sales were RMB17.05 billion (US$2.51 billion) for the second quarter of 2026, representing an increase of 1.0% from RMB16.88 billion for the same period of 2025, and an increase of 55.0% from RMB11.00 billion for the first quarter of 2026. The quarter-over-quarter increase was mainly attributable to higher vehicle deliveries.

Revenues from services and others were RMB2.70 billion (US$0.40 billion) for the second quarter of 2026, representing an increase of 93.9% from RMB1.39 billion for the same period of 2025 and an increase of 32.6% from RMB2.03 billion for the first quarter of 2026. The year-over-year and quarter-over-quarter increases were primarily attributable to increased revenues from (i) technical research and development services ("technical R&D services") rendered to a car manufacturer (the "Manufacturer") with the successful achievement of certain key milestones in the current period, under the agreement entered into with the Manufacturer; and (ii) parts and accessories sales.

Cost of sales was RMB15.66 billion (US$2.31 billion) for the second quarter of 2026, representing an increase of 3.7% from RMB15.11 billion for the same period of 2025 and an increase of 51.3% from RMB10.35 billion for the first quarter of 2026. The quarter-over-quarter increase was mainly in line with vehicle deliveries as described above.

Gross margin was 20.7% for the second quarter of 2026, compared with 17.3% for the same period of 2025 and 20.6% for the first quarter of 2026.

Vehicle margin was 12.1% for the second quarter of 2026, compared with 14.3% for the same period of 2025 and 12.1% for the first quarter of 2026. The year-over-year decrease was due to product generation transition.

Services and others margin was 75.1% for the second quarter of 2026, compared with 53.6% for the same period of 2025 and 66.5% for the first quarter of 2026. The year-over-year and quarter-over-quarter increases were attributable to the aforementioned revenue from technical R&D services and parts and accessories sales.

Research and development expenses were RMB2.91 billion (US$0.43 billion) for the second quarter of 2026, representing an increase of 32.1% from RMB2.21 billion for the same period of 2025 and an increase of 0.3% from RMB2.91 billion for the first quarter of 2026. The year-over-year increase was mainly due to higher expenses related to the development of new vehicle models and AI-related technologies as the Company expanded its product portfolio to support future growth.

Selling, general and administrative expenses were RMB2.50 billion (US$0.37 billion) for the second quarter of 2026, representing an increase of 15.2% from RMB2.17 billion for the same period of 2025 and an increase of 32.5% from RMB1.88 billion for the first quarter of 2026. The year-over-year increase was primarily due to higher marketing and advertising expenses. The quarter-over-quarter increase was primarily due to the higher commission to the franchised stores and higher marketing and advertising expenses.

Other income, net was RMB0.14 billion (US$0.02 billion) for the second quarter of 2026, representing a decrease of 42.2% from RMB0.24 billion for the same period of 2025 and a decrease of 24.7% from RMB0.18 billion for the first quarter of 2026. The year-over-year and quarter-over-quarter decreases were primarily due to the decrease in receipt of government subsidies.

Fair value gain on derivative liability relating to the contingent consideration was a gain of RMB0.05 billion (US$0.01 billion) for the second quarter of 2026, compared with a gain of RMB0.03 billion for the same period of 2025 and a gain of RMB0.05 billion for the first quarter of 2026. This non-cash gain resulted from the fair value change of the contingent consideration related to the acquisition of DiDi Global Inc. ("DiDi")'s smart auto business.

Loss from operations was RMB1.14 billion (US$0.17 billion) for the second quarter of 2026, compared with RMB0.93 billion for the same period of 2025 and RMB1.87 billion for the first quarter of 2026.

Non-GAAP loss from operations, which excludes share-based compensation expenses and fair value gain on derivative liability relating to the contingent consideration, was RMB1.04 billion (US$0.15 billion) for the second quarter of 2026, compared with a loss of RMB0.84 billion for the same period of 2025 and a loss of RMB1.78 billion for the first quarter of 2026.

Net loss was RMB1.34 billion (US$0.20 billion) for the second quarter of 2026, compared with a loss of RMB0.48 billion for the same period of 2025 and a loss of RMB1.78 billion for the first quarter of 2026.

Non-GAAP net loss, which excludes share-based compensation expenses and fair value gain on derivative liability relating to the contingent consideration, was RMB1.24 billion (US$0.18 billion) for the second quarter of 2026, compared with a loss of RMB0.39 billion for the same period of 2025 and a loss of RMB1.69 billion for the first quarter of 2026.

Net loss attributable to ordinary shareholders of XPENG was RMB1.34 billion (US$0.20 billion) for the second quarter of 2026, compared with a loss of RMB0.48 billion for the same period of 2025 and a loss of RMB1.78 billion for the first quarter of 2026.

Non-GAAP net loss attributable to ordinary shareholders of XPENG, which excludes share-based compensation expenses and fair value gain on derivative liability relating to the contingent consideration, was RMB1.24 billion (US$0.18 billion) for the second quarter of 2026, compared with a loss of RMB0.39 billion for the same period of 2025 and a loss of RMB1.69 billion for the first quarter of 2026.

Basic and diluted net loss per ADS were both RMB1.40 (US$0.21) for the second quarter of 2026, compared with RMB0.50 basic and diluted net loss per ADS for the second quarter of 2025 and RMB1.87 basic and diluted net loss per ADS for the first quarter of 2026.

Non-GAAP basic and diluted net loss per ADS were both RMB1.29 (US$0.19) for the second quarter of 2026, compared with RMB0.41 non-GAAP basic and diluted net loss per ADS for the second quarter of 2025 and RMB1.76 non-GAAP basic and diluted net loss per ADS for the first quarter of 2026.

Balance Sheets

As of June 30, 2026, the Company had a cash position of RMB40.48 billion (US$5.97 billion), compared with RMB42.09 billion as of March 31, 2026.

Business Outlook

For the third quarter of 2026, the Company expects:

• Deliveries of vehicles to be between 115,000 and 121,000, representing a year-over-year change of approximately -0.87% to +4.30%, and a quarter-over-quarter increase of approximately 11.33% to 17.14%.
  
  
• Total revenues to be between RMB21.7 billion and RMB23.4 billion, representing a year-over-year increase of approximately 6.47% to 14.81%, and a quarter-over-quarter increase of approximately 9.91% to 18.52%.

The above outlook is based on the current market conditions and reflects the Company's preliminary estimates of market and operating conditions, and customer demand, which are all subject to change.

Conference Call

The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on August 24, 2026 (8:00 PM Beijing/Hong Kong Time on August 24, 2026).

For participants who wish to join the call by phone, please access the link provided below to complete the pre-registration process and dial in 5 minutes prior to the scheduled call start time. Upon registration, each participant will receive dial-in details to join the conference call.

Event Title:                XPENG Second Quarter 2026 Earnings Conference Call
Pre-registration link:  https://s1.c-conf.com/diamondpass/10056093-aweri7.html

Additionally, a live and archived webcast of the conference call will be available on the Company's investor relations website at http://ir.xiaopeng.com.

A replay of the conference call will be accessible approximately an hour after the conclusion of the call until September 1, 2026, by dialing the following telephone numbers:

About XPENG

XPENG is a leading global Physical AI company, dedicated to bringing artificial intelligence into the physical world to reshape future mobility and smart living. Through in-house R&D, XPENG has developed a full-stack Physical AI architecture spanning Turing AI chips, world foundation models, and highly integrated software and hardware applications. This unified technology foundation of XPENG powers an expansive product portfolio of smart EVs, robotaxis, and humanoid robots, advancing the deployment of Physical AI at scale. Headquartered in Guangzhou, China, XPENG is dual-primary listed on the New York Stock Exchange and the Hong Kong Stock Exchange. With global capabilities across R&D, manufacturing, sales, and services, XPENG drives continuous technological innovation and fosters an open Physical AI ecosystem, making life smarter, safer, and better for users worldwide. For more information, please visit https://www.xpeng.com/.

Use of Non-GAAP Financial Measures

The Company uses non-GAAP measures, such as non-GAAP loss from operations, non-GAAP net loss, non-GAAP net loss attributable to ordinary shareholders, non-GAAP basic loss per ordinary share and non-GAAP basic loss per ADS, in evaluating its operating results and for financial and operational decision-making purposes. By excluding the impact of share-based compensation expenses and fair value gain on derivative liability relating to the contingent consideration, the Company believes that the non-GAAP financial measures help identify underlying trends in its business and enhance the overall understanding of the Company's past performance and future prospects. The Company also believes that the non-GAAP financial measures allow for greater visibility with respect to key metrics used by the Company's management in its financial and operational decision-making. The non-GAAP financial measures are not presented in accordance with U.S. GAAP and may be different from non-GAAP methods of accounting and reporting used by other companies. The non-GAAP financial measures have limitations as analytical tools and when assessing the Company's operating performance, investors should not consider them in isolation, or as a substitute for net loss or other consolidated statements of comprehensive loss data prepared in accordance with U.S. GAAP. The Company encourages investors and others to review its financial information in its entirety and not rely on a single financial measure. The Company mitigates these limitations by reconciling the non-GAAP financial measures to the most comparable U.S. GAAP performance measures, all of which should be considered when evaluating the Company's performance.

For more information on the non-GAAP financial measures, please see the table captioned "Unaudited Reconciliations of GAAP and non-GAAP Results" set forth in this announcement.

Exchange Rate Information

This announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars and from U.S. dollars to RMB are made at a rate of RMB6.79 to US$1.00, the exchange rate on June 30, 2026, set forth in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the RMB or U.S. dollar amounts referred to could be converted into U.S. dollars or RMB, as the case may be, at any particular rate or at all.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Statements that are not historical facts, including statements about XPENG's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: XPENG's goal and strategies; XPENG's expansion plans; XPENG's future business development, financial condition and results of operations; the trends in, and size of, China's EV market; XPENG's expectations regarding demand for, and market acceptance of, its products and services; XPENG's expectations regarding its relationships with customers, suppliers, third-party service providers, strategic partners and other stakeholders; general economic and business conditions; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in XPENG's filings with the United States Securities and Exchange Commission. All information provided in this announcement is as of the date of this announcement, and XPENG does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For Investor Enquiries
IR Department
XPeng Inc.
E-mail: [email protected]

Jenny Cai
Piacente Financial Communications
Tel: +1-212-481-2050 or +86-10-6508-0677
E-mail: [email protected]

For Media Enquiries
PR Department
XPeng Inc.
E-mail: [email protected]

深耕大眾旅遊市場 核心業務穩健增長
積極擁抱人工智能提升運營效率

香港2026年8月24日 /美通社/ -- 中國領先的綜合旅遊平台同程旅行控股有限公司（「同程旅行」或「公司」，連同其附屬公司（統稱「集團」），股票代號：0780.HK）今天公佈其截至2026年6月30日止三個月（「2026年第二季度」）及六個月（「回顧期」或「2026年上半年」）之未經審核綜合業績。

同程旅行聯席董事長﹑執行董事兼首席執行官馬和平先生表示：「2026第二季度，中國旅遊市場的外部環境充滿挑戰，燃油附加費大幅增加對長途旅遊需求造成壓力。儘管面臨不利影響，我們對公司業務及整體中國旅遊業的發展前景依然保持信心。中國政府進一步強化旅遊業作為國民經濟戰略性支柱產業的地位，為行業的長期增長奠定堅實基礎。回顧期內，同程旅行保持敏銳洞察與快速響應，積極擁抱AI帶來的技術變革新機遇，季度內再次取得穩健業績。」

持續深耕大眾旅遊市場   年累計服務人次2,044.3百萬

憑藉卓越的運營能力，同程旅行進一步鞏固在中國大眾旅遊市場的地位。集團通過高效的用戶互動措施及全面的產品供給，成功建立龐大的用戶基數。截至2026年上半年，集團的平均月付費用戶及年付費用戶分別為45.1百萬人及253.9百萬人。十二個月累計服務人次2,044.3百萬。截至2026年6月30日，集團超過87%的註冊用戶來自中國非一線城市。

回顧期內，同程旅行持續優化在微信生態系統內的運營效率。同時，作為獲取新用戶的核心渠道，集團的自有APP保持強勁的增長勢頭，其日活躍用戶在五一假期前達到歷史新高。為順應消費者追求儀式感與鬆弛感的新趨勢，集團推出主題營銷活動，以加強與年輕用戶群體的互動。

同程旅行重視用戶價值，積極投入會員計劃並優化用戶權益。回顧期內，集團通過提供更多專屬權益並提升服務質量，以加強與高價值會員的互動。此外，集團為用戶提供豐富的旅遊產品及服務，以滿足用戶在旅程中不斷變化的需求。這些舉措進一步提高用戶復購率，並增強用戶忠誠度。

核心在線旅遊平台業務保持穩健增長   其他業務收入同比增長46.3%

同程旅行的核心在線旅遊平台業務繼續保持增長勢頭。回顧期內，集團的核心在線旅遊平台業務總收入同比增加12.7%至人民幣8,794.1百萬元。主要受2026第二季度ADR與酒店間夜量穩健增長所推動，2026年上半年集團的住宿業務收入同比增加11.1%至人民幣2,845.1百萬元。受益於消費者偏好向高品質酒店轉移的結構性變化，2026年第二季度集團平台上高品質酒店間夜量佔比進一步提升。國際住宿業務方面，集團持續深化與全球供應商的合作，並進一步優化產品及服務供給，以更好地滿足用戶需求。

集團的交通業務受第二季度機票價格高企抑制出行需求的影響，2026年上半年整體收入同比增加2.1%至人民幣3,962.2百萬元。回顧期內，集團致力於提升用戶體驗，由算法驅動的慧行系統持續為用戶提供多元、可靠的端到端出行解決方案。同時，集團進一步將短途交通服務融入用戶的出行旅程中，為用戶提供更加順暢及便捷的出行體驗。在國際機票業務方面，集團維持具有競爭力的定價策略，同時進一步提升服務質量，以強化用戶心智。2026年第二季度，集團國際機票收入保持強勁的增長勢頭。

同程旅行的其他業務錄得顯著增長。回顧期內，其他業務的收入同比增加46.3%至人民幣1,986.8百萬元，主要受酒店管理業務的出色表現所推動。集團的藝龍酒店科技平台戰略聚焦受市場認可的品牌，延續快速擴張的態勢，同時憑藉技術能力提升運營效率。萬達酒店及度假村則採取精細化的擴張策略，聚焦核心城市與熱門旅遊目的地，以提升其在中國高端酒店的市場份額。截至2026年6月30日，集團在營運的酒店總數超過3,500家，另有超過2,000家酒店在籌備中。

積極運用AI技術提升營運效率  構建智能旅遊新體驗

作為一家創新驅動型企業，同程旅行致力於運用AI技術以把握AI時代的增長機遇，同時提升公司整體的營運效率。集團積極與領先的第三方AI平台開展戰略合作。作為首批接入微信AI助手的在線旅遊平台之一，集團正積極參與微信AI生態系統的共建，聚焦於在該生態系統內打磨並驗證其業務能力。同時，集團持續迭代自有AI行程規劃智能體DeepTrip。於2026第二季度，集團增強DeepTrip的記憶能力，使其能夠結合用戶的歷史偏好，生成更為精準化、定製化的旅遊行程。

在客戶服務方面，集團進一步深化AI驅動的自動化能力。在常規用戶諮詢場景已實現高度自動化的基礎上，集團將AI應用擴展至更多客服場景，顯著提升客戶服務效率及用戶體驗。此外，集團將AI深度嵌入到所有人工服務環節中，為客戶服務團隊配置AI工具箱，幫助其更好地理解用戶訴求，從而實現響應速度與準確率的提升。

展望未來，憑藉清晰的戰略佈局及卓越的執行能力，同程旅行完全有能力應對短期的市場不確定性，並把握長期增長機遇。集團將繼續專注於核心在線旅遊平台業務，鞏固公司在中國大眾旅行市場的地位，同時積極拓展國際業務。酒店管理業務方面，集團將加快酒店網絡擴張，同時提升運營效率。此外，集團將加大力度應用AI技術，以把握潛在增長機遇並提升運營效率。同程旅行將繼續致力於提升公司的ESG表現，為所有利益相關者創造可持續的長期價值。

-完-

關於同程旅行控股有限公司（香港聯交所股份代號：0780.HK）

同程旅行是滿足用戶旅遊需求的一站式平台。同程旅行秉持「讓旅行更簡單、更快樂」的使命，為用戶提供幾乎涵蓋旅遊所有方面的全面創新產品和服務選擇，包括交通、住宿、景點門票預訂、酒店管理、度假產品以及各種配套增值旅遊產品與服務，廣泛覆蓋了多個出行和度假場景。主要通過其在線平台（包括其騰訊旗下平台、自有移動應用程式、輕應用及其他渠道）來滿足用戶在整個旅途中不斷變化的旅遊需要。

作為科技驅動型公司，同程旅行借助大數據及人工智能能力，更好地瞭解用戶偏好和行為，向用戶提供定制化產品及服務。同程旅行重點佈局中國下沉市場，利用其多元化的流量渠道、產品的創新能力及靈活的運營策略。透過對用戶需求的深入瞭解及先進技術能力，同程旅行正逐步改變消費者對線上旅遊行業的期望，使得旅遊過程更方便、更具個性化及更愉快。同程旅行致力開發並應用先進科技，從線上旅遊平台轉型為智慧出行管家。

欲瞭解更多資訊，請瀏覽集團網站: https://www.tongchengir.com

NVIDIA Corporation (NVDA.US) reached a licensing agreement with AI startup Poolside to build open-weight AI models, vying against Chinese models such as DeepSeek and Kimi K3, while also being expected to pose a direct challenge to major US AI companies including OpenAI and Anthropic, the Wall Street Journal, citing sources, reported.

Poolside was founded in 2023 by software developer Eiso Kant and former GitHub Chief Technology Officer Jason Warner. The company previously sent a letter to shareholders announcing a major business restructuring.

NVIDIA will invest USD1 billion in Poolside at a pre-money valuation of USD12 billion, according to the report, citing the letter. It will also pay USD6 billion to obtain licensing rights for Poolside's technology and recruit most of its engineers.
~

AASTOCKS Financial News
Website: www.aastocks.com

US President Donald Trump disclosed that he carried out more than 1,000 financial asset switches in June, indicating a large-scale reshuffle of his investment portfolio.

He adjusted holdings across stocks, bonds and exchange-traded funds (ETFs) throughout June, according to the latest filing submitted by Trump on August 22. As the filing only listed value ranges for each transaction instead of exact figures, the total transaction value ranged from USD78.1 million to USD263.1 million. Securities purchases exceeded USD49 million, while sales amounted to at least USD28.5 million.

The filing reflects investment operations conducted on behalf of Trump, but does not fully reveal the overall portfolio holdings. The disclosure did not specify actual trading amounts, nor did it reveal the scale of his holdings in any particular securities.

Among the 1,051 transactions, the largest was the sale of Vanguard Dividend Appreciation Index Fund ETF shares on June 22, with a transaction value ranging from USD5 million to USD25 million. On the same day, he also bought Fidelity National Information Services, Inc. (FIS.US) and Home Depot Inc. (HD.US), with each transaction ranging from USD1 million to USD5 million. Both represented the largest purchases of those shares during June, although he also sold part of his Fidelity holdings.

Trump sold shares of Meta Platforms, Inc. (META.US) and Motorola Solutions, Inc. (MSI.US) on June 18, with each transaction valued between USD1 million and USD5 million. On the same day, he bought Berkshire Hathaway (BRK.B.US), Cintas Corporation (CTAS.US), Visa Inc. (V.US) and Mastercard Incorporated (MA.US), with each transaction also ranging from USD1 million to USD5 million. These trades took place one day after the market declined amid concerns over the outlook for monetary policy. June 17 marked the conclusion of Federal Reserve Chair Kevin Warsh's first meeting, and stocks rebounded on June 18.
~

AASTOCKS Financial News
Website: www.aastocks.com

NVIDIA Corporation (NVDA.US) is discussing potential cooperation with South Korean AI chip design company Rebellions, which may include technological collaboration, investment, or even an acquisition, Bloomberg, citing sources, reported.

NVIDIA CEO Jensen Huang reportedly met Rebellions co-founder and CEO Sunghyun Park in California this week and discussed potential partnership opportunities.

Previously, Rebellions had raised approximately USD850 million from investors including SK Hynix, Samsung Venture Investment and Arm Holdings plc (ARM.US). Its latest valuation was approximately USD2.3 billion.
~

AASTOCKS Financial News
Website: www.aastocks.com

BEIJING, Aug. 21, 2026 /PRNewswire/ -- Zoomlion Heavy Industry Science & Technology Co., Ltd. ("Zoomlion" or "the Company"; 1157.HK) is showcasing its embodied intelligence technologies and robotic products for industrial applications at the 2026 World Robot Conference (WRC), taking place from Aug. 19-23, 2026, in Beijing, China.

Since 2015, the WRC has brought together companies, researchers and industry stakeholders to showcase advances in robotics and practical applications. The 2026 edition focuses on human-robot collaboration and closer alignment between technology development and industrial demand.

A Showcase for Zoomlion's Embodied Intelligence Systems

At the WRC, Zoomlion is presenting the bipedal humanoid robot Z01, the wheeled humanoid robot Z03, and the quadrupedal robot dogs D15 and D40, as well as its self-developed joint modules.

These robotic products reflect Zoomlion's application of embodied intelligence to address practical manufacturing pain points such as flexible sorting, precision assembly and wire-harness handling, with each robot configured for the requirements of its assigned task.

Zoomlion's booth features Robot Ops, an embodied intelligence operating system that debuted at Hannover Messe in April 2026. Designed as a professional development platform for embodied intelligence in the Software 3.0 era, Robot Ops integrates four core modules: basic tools, imitation learning, reinforcement learning and task orchestration. It supports a closed-loop development lifecycle covering data collection, model training, simulation and validation, as well as deployment and operations.

The platform is designed to support applications involving humanoid robots, industrial robots, construction machinery and autonomous driving, empowering industries through a single integrated platform while providing a standardized and replicable engineering pathway for the large-scale deployment of embodied intelligence.

Alongside Robot Ops, Zoomlion is also presenting ZBrain, an embodied intelligence system which enables traditional industrial robots to move beyond fixed-program execution and become intelligent operating units capable of sensing their environment, understanding tasks, making autonomous decisions and executing closed-loop operations.

Empowered by ZBrain, users can issue task instructions, after which the system autonomously performs detection, planning, execution and verification. It is designed to support high-mix, low-volume production, significantly shortening deployment timelines, accelerating changeover cycles and lowering the barrier to adoption.

At the conference, Zoomlion is highlighting capabilities that are grounded in real-world testing. Zoomlion has validated its robots across nearly 20 manufacturing scenarios at Zoomlion Smart City, where they have been deployed in active manufacturing environments. This operational experience provides the data and know-how needed to move intelligent technologies and robotic products toward large-scale industrial deployment.

Industrial and Interactive Demonstrations

Visitors can experience the capabilities of Zoomlion's robots firsthand through a series of industrial and interactive demonstrations. The Z03 performs material picking, sorts irregularly shaped items and completes the preassembly of rearview mirrors, while the Z01 handles and organizes wire harnesses. The demonstrations also include synchronized dance performances, robot-guided tours and gesture-based interactions with Z01.

The Company is advancing embodied intelligence from laboratory research to deployable industrial applications and supporting intelligent manufacturing across industries.

Visitors to the WRC 2026 can find Zoomlion at Booth D403 in Hall D.